Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Res. 2011 Oct 10;71(23):7198–7206. doi: 10.1158/0008-5472.CAN-11-1514

Figure 3.

Figure 3

EGFRWT kinase inhibition attenuates signaling pathways. A–B, Immunoblot of total cell extracts from vehicle- and gefitinib-treated (10 μM) TGFα-EGFRWT;InkΔ2/3−/−tumor cultures analyzed for the presence of (A) the indicated phosphotyrosine residues (B) the activation status of the canonical MAPK members Mek1/2 and Erk1/2.β-tubulin and dynamin are used as internal loading controls.